Nitazoxanide
It is a commercial antiprotozoal agent with an antiviral capacity
against a wide range of viruses, including human and animal
coronaviruses, reported to be resistance to 2019-nCoV, at low micromolar
concentrations, such as - EC50 = 2.12 μM; CC50 > 35.53 μM;
SI > 16.76 [10]. Further in vivo evaluation of this
medication is suggested against 2019-nCoV infection. Authorized for
diarrhea therapy, Neitazoxanide has the potentiality to inhibit
2019-nCoV and thus, needs clinical trials to determine the antiviral
efficacy of this drug [12] [15].